Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

The company announced that an independent CRO successfully reproduced ERNA-101 combination data in a larger preclinical study, strengthening confidence in the program. This update supports its progression toward an IND submission, indicating improved validation of the underlying preclinical findings.

Analysis

The company announced that an independent CRO successfully reproduced ERNA-101 combination data in a larger preclinical study, strengthening confidence in the program. This update supports its progression toward an IND submission, indicating improved validation of the underlying preclinical findings.